← Issue №16/ week of Oct 18, 2026/Colorectal

Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study.

From GI Signals issue №16: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal prospective cohort · n=334,882 · Oct 12, 2026 · BMC Gastro · IF 2.5

Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study.

New evidencecolorectal cancerepidemiologybiomarkerartificial intelligence
Clinical takeawayObservational, with likely residual confounding and survivor bias; do not start or extend a P2Y12 inhibitor for cancer benefit. Continue it for its cardiovascular indication, including in patients with colorectal cancer.
What it foundP2Y12 inhibitor use reduced CRC mortality (HR 0.42; 95% CI, 0.29-0.60) compared to non-users when initiated after CRC diagnosis in patients with ASCVD.
ContextParallels the aspirin literature; no randomised trial of P2Y12 inhibition in CRC exists.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Fuchs M … Ludvigsson JF · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
← Read the whole of issue №16 Every paper GI Signals surfaces gets a page like this one. All issues